𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Intravenous iron requirement in adult hemodialysis patients

✍ Scribed by Timothy V. Nguyen

Publisher
Wiley (John Wiley & Sons)
Year
2006
Tongue
English
Weight
94 KB
Volume
35
Category
Article
ISSN
0090-2934

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

FDA report: Ferumoxytol for intravenous
FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease
✍ Min Lu; Martin H. Cohen; Dwaine Rieves; Richard Pazdur πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 88 KB

## Abstract On June 30, 2009, the United States Food and Drug Administration (FDA) approved ferumoxytol (Ferahemeβ„’ injection, AMAG Pharmaceuticals), an iron‐containing product for intravenous (IV) administration, for the treatment of iron deficiency anemia in adult patients with chronic kidney dise

Anemia Management in Adult Chronic Hemod
Anemia Management in Adult Chronic Hemodialysis Patients Using Darbepoetin Alfa Protocol
✍ Timothy Nguyen; Debra Wells πŸ“‚ Article πŸ“… 2007 πŸ› Wiley (John Wiley & Sons) 🌐 English βš– 125 KB

## Abstract ## BACKGROUND Data on darbepoetin alfa for anemia management in patients with chronic kidney disease (CKD) is scarce when compared with epoetin alfa. Clinical experiences of using darbepoetin alfa, dosing guide, and average weekly requirements are discussed in this article. ## METHODS

Totally implanted device for long-term i
Totally implanted device for long-term intravenous chemotherapy: Experience in 123 adult patients with solid neoplasms
✍ Puig-la Calle, Jorge; LΓ³pez SΓ‘nchez, Santos; Piedrafita Serra, EncarnaciΓ³n; Hono πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 601 KB

Vascular access in patients receiving prolonged chemotherapy is a difficult problem. This led to the introduction of a totally implanted device. We intend to assess the efficacy of this device in a subset of oncologic patients. Between May 1989 and November 1992, 129 devices were placed in 123 adult